Form 8-K - Current report:
SEC Accession No. 0000950170-25-046769
Filing Date
2025-03-28
Accepted
2025-03-28 16:08:33
Documents
15
Period of Report
2025-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K srzn-20250324.htm   iXBRL 8-K 129758
2 EX-10.1 srzn-ex10_1.htm EX-10.1 471853
3 EX-10.2 srzn-ex10_2.htm EX-10.2 147902
4 EX-10.3 srzn-ex10_3.htm EX-10.3 155059
5 EX-10.4 srzn-ex10_4.htm EX-10.4 265475
  Complete submission text file 0000950170-25-046769.txt   1480177

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT srzn-20250324.xsd EX-101.SCH 46365
18 EXTRACTED XBRL INSTANCE DOCUMENT srzn-20250324_htm.xml XML 6600
Mailing Address 171 OYSTER POINT BLVD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-475-2820
Surrozen, Inc./DE (Filer) CIK: 0001824893 (see all company filings)

EIN.: 301374889 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39635 | Film No.: 25786039
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)